Owlstone Medical

owlstone medical has developed a breathalyzer for disease. with a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5b in healthcare costs. owlstone medical’s breath biopsy® platform is a new diagnostic modality capable of detecting disease biomarkers in breath. the award winning reciva breath sampler ensures reliable collection of breath samples. voc (volatile organic compound) biomarkers present in breath are analyzed with high sensitivity and selectivity using proven microchip chemical sensor technology (field asymmetric ion mobility spectrometry, faims). the breath biopsy platform has the potential to revolutionize early detection and precision medicine, with applications in cancer and a wide range of other conditions. breath biopsy enables disease to be detected earlier, when treatments are more effective and more lives can be saved. by identifying patients most likely